Who is the CEO of GC WellBeing?

According to the DART company overview, GC WellBeing's representative director is 김상현 (name as registered in Korean). The company was founded on 2004-09-02.

Where is GC WellBeing listed?

GC WellBeing trades on the Korea Exchange KOSDAQ market under the ticker 234690. Its fiscal year ends in December.

Does GC WellBeing pay a dividend?

Yes. For fiscal 2025, GC WellBeing paid a cash dividend of ₩140 per common share, a 1.5% yield as stated in its annual report, with a payout ratio of 24.8%. The prior year's dividend was ₩120.

Does GC WellBeing have any recent filing signals?

Signals detected automatically from DART filings and quarterly results: Revenue +30% (latest quarterly revenue up more than 30% year on year); Dividend grower (dividend per share raised three years in a row). These are factual flags, not investment advice.

Which companies are in the same industry as GC WellBeing?

Under the Korean Standard Industrial Classification recorded on DART, GC WellBeing is grouped with 107 other listed companies in pharmaceuticals. The most covered in Korean news over the past 30 days are Hanmi Pharm, Yuhan and Daewoong Pharma.

GC WellBeing KRX:234690KOSDAQ

녹십자웰빙 · Korean news coverage and regulatory filings, organized.

한국어

Articles, 24h1

Articles, 7 days1

DART filings, 7 days1

Articles tracked7since Sep 11

In Q2 2026, GC WellBeing reported revenue of ₩52.1bn, up 33.8% year on year, and operating profit of ₩4.6bn. GC WellBeing (녹십자웰빙) appeared in 1 Korean news article and 1 DART filing over the past seven days. Coverage peaked on Oct 29 with 1 article.

Filing signals Revenue +30% Dividend grower Screener

GC WellBeing quarterly results consolidated, KRW

Quarter	Revenue	YoY	Operating profit	Net income
Q2 2026	₩52.1bn	+33.8%	₩4.6bn margin 8.9%	₩4.0bn
Q1 2026	₩49.1bn	+41.3%	₩4.8bn margin 9.8%	−₩3.0bn
Q4 2025 derived	₩48.7bn	+38.8%	₩2.9bn margin 5.9%	₩849m
Q3 2025	₩42.3bn	+28.0%	₩5.2bn margin 12.3%	₩3.7bn
Q2 2025	₩38.9bn	+19.2%	₩4.2bn margin 10.8%	₩342m
Q1 2025	₩34.8bn	+5.3%	₩5.0bn margin 14.3%	₩5.1bn
Q4 2024 derived	₩35.1bn	+3.6%	₩2.3bn margin 6.4%	₩589m
Q3 2024	₩33.0bn	+12.6%	₩3.9bn margin 11.9%	₩2.3bn

Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.

GC WellBeing top stories 2 weeks, by number of outlets

1
녹십자웰빙, 11월 4~5일 기관에 3분기 실적 설명
1 outlets · 1 articlesFirst report Oct 29 20:08 비건뉴스

Latest GC WellBeing news Korean headlines

Oct 2920:08

녹십자웰빙, 11월 4~5일 기관에 3분기 실적 설명
비건뉴스
Oct 1313:55

[공모주 SWOT] 엠에스바이오 피어그룹 녹십자웰빙·메디톡스, 사업 유사성보다 수익성?
녹색경제신문Medy-Tox
Oct 722:14

녹십자웰빙·365mc, RZL-012 국내 개발 협력
비건뉴스Partnership
Sep 3008:19

녹십자웰빙, 라이넥 20% 가격인상·IV 확장…내년 실적 확대 기대
메디코파마
Sep 2823:10
[적중! 대박 예감] '녹십자웰빙, 나노신소재' 내일장 예감 좋은 대박 종목?
MTNAdvanced Nano Products
1 more on this story · 1 outlets
- [적중! 대박 예감] '녹십자웰빙, 나노신소재' 내일장 예감 좋은 대박 종목?머니투데이 · Sep 28 23:28
Sep 1306:00

[바이오e종목] “턱살 정리”…비만 올라탄 녹십자웰빙, 새로운 캐시카우될까
조선비즈

Articles per day 2 weeks

129

Company profile

CEO: 김상현
Industry: Pharmaceuticals
Founded: 2004-09-02
Fiscal year-end: December
Head office: 서울특별시 성동구
Website: greencrosswb.com
Quotes & chart: Naver Securities (Korean)

From the DART company overview.

GC WellBeing dividends annual report

Korea dividend rankings

Year	Per share	Yield	Payout
FY2025	₩140	1.5%	24.8%
FY2024	₩120	1.2%	30.1%
FY2023	₩100	1.4%	26.3%

Raised 3 years in a row

Same industry Pharmaceuticals

All in industry

Company	Latest quarter op. profit	Articles 30d
Hanmi Pharm	₩131bn	655
Yuhan	₩66.9bn	484
Daewoong Pharma	₩68.1bn	372
GC Biopharma	₩1.7bn	326
DongKookPharmaceutical	₩26.1bn	259
Daewon Pharmaceutical	−₩9m	197
Kwangdong Pharmaceutical	₩2.8bn	188
JW Pharmaceutical	₩33.3bn	185

Compare GC WellBeing side by side with these companies

GC WellBeing DART filings

Oct 2916:22

Investor relations event 기업설명회(IR)개최
Other
Sep 1415:37

Investor relations event 기업설명회(IR)개최
Other

Mentioned alongside 2 weeks

No co-mentioned companies yet.

GC WellBeing FAQ

Who is the CEO of GC WellBeing?: According to the DART company overview, GC WellBeing's representative director is 김상현 (name as registered in Korean). The company was founded on 2004-09-02.
Where is GC WellBeing listed?: GC WellBeing trades on the Korea Exchange KOSDAQ market under the ticker 234690. Its fiscal year ends in December.
What were GC WellBeing's latest quarterly results?: In Q2 2026, GC WellBeing reported revenue of ₩52.1bn, up 33.8% year on year, and operating profit of ₩4.6bn. Figures come from reports filed on DART.
Does GC WellBeing pay a dividend?: Yes. For fiscal 2025, GC WellBeing paid a cash dividend of ₩140 per common share, a 1.5% yield as stated in its annual report, with a payout ratio of 24.8%. The prior year's dividend was ₩120.
Does GC WellBeing have any recent filing signals?: Signals detected automatically from DART filings and quarterly results: Revenue +30% (latest quarterly revenue up more than 30% year on year); Dividend grower (dividend per share raised three years in a row). These are factual flags, not investment advice.
Which companies are in the same industry as GC WellBeing?: Under the Korean Standard Industrial Classification recorded on DART, GC WellBeing is grouped with 107 other listed companies in pharmaceuticals. The most covered in Korean news over the past 30 days are Hanmi Pharm, Yuhan and Daewoong Pharma.